6 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Development of a liver-targeted stearoyl-CoA desaturase (SCD) inhibitor (MK-8245) to establish a therapeutic window for the treatment of diabetes and dyslipidemia.
Merck Frosst Centre For Therapeutic Research
2-Aryl benzimidazoles: human SCD1-specific stearoyl coenzyme-A desaturase inhibitors.
Merck Frosst Centre For Therapeutic Research
Potent, orally bioavailable, liver-selective stearoyl-CoA desaturase (SCD) inhibitors.
Gilead Sciences
Novel, potent, selective, and metabolically stable stearoyl-CoA desaturase (SCD) inhibitors.
Cv Therapeutics
T-3364366 Targets the Desaturase Domain of Delta-5 Desaturase with Nanomolar Potency and a Multihour Residence Time.
Takeda Pharmaceutical